Immatics (IMTX) Stock Price

Immatics Price

NASDAQ·CLOSED
6.45
​
Market closed

Over the last 7 years Immatics grew revenue by 44.9% annually, reaching 55.27 M EUR. For Immatics, the net margin of -415.1% is down versus -287.7% a few years ago. The consensus 12-month price target for Immatics is 22.31 EUR, about 245.8% above where the stock trades today. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus.

Immatics stock price

Access this data via the Eulerpool API

Immatics business model & stock analysis

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 210 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Frequently asked questions about Immatics

Analysts currently set an average price target of 22.31 EUR for the Immatics stock (median: 22.31 EUR), implying +245.8 % versus the latest price. The consensus is based on 16 analyst ratings.

16 analysts currently rate the Immatics stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Immatics to generate revenue of 42.96 M EUR and earnings per share of -1.97 EUR.

The Immatics share (IMTX) is listed on 4 stock exchanges, including: NASDAQ (IMTX), Frankfurt (4A3.F), München (4A3.MU), Düsseldorf (4A3.DU).

The expected revenue of Immatics is 42.96 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Immatics is -247.71 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Immatics is currently -3.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immatics stock.

The price-to-sales ratio (P/S) of Immatics is currently 18.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immatics stock.

The Eulerpool Quality Score for Immatics is 1/10.

The ISIN of Immatics is NL0015285941. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Immatics is A2P72S. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Immatics is IMTX. The ticker symbol is used to trade Immatics shares on the stock exchange.

Fair ValueTerminal
6.77 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
181,805.31 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website immatics.com
Country
Currency
EUR
Initial public offering
Jul 2, 2020
ISIN
NL0015285941
Cusip
N44445109
Market capitalization
784.25 M EURSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-3.28
P/Ee 2027
-3.15
P/Ee 2028
-3.62
P/Ee 2029
-6.53
P/Ee 2030
-45.00
P/Se
18.93
EV/EBIT
—
P/B Ratio
1.39
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-40.37 %
Last updated Oct 12, 2026, 7:11 AM

Immatics Peer Group

Immatics Ticker

DÜSSELDORF · 4A3.DUFRANKFURT · 4A3.FMUNICH · 4A3.MUNASDAQ · IMTX

Immatics FIGI

IMTX:US · BBG00VTL2H76IMTX:UA · BBG00VTL2H85IMTX:UC · BBG00VTL2H94IMTX:UN · BBG00VTL2HC0IMTX:UP · BBG00VTL2HD9IMTX:UB · BBG00VTL2HG6IMTX:UM · BBG00VTL2HJ3IMTX:UX · BBG00VTL2HK1IMTX:UR · BBG00VTL2HL0IMTX:UD · BBG00VTL2HQ5IMTX:UF · BBG00VTL2HT2IMTX:VY · BBG00VTL2HV9

All fundamentals and in-depth analysis of Immatics

Our stock analysis for Immatics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immatics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.